RxDoctor Payments Data

Minhaj Siddiqi, MD

Psychiatry · Utica, NYNPI 1598858458

Payments from drug & device makers

$3,054in general payments, 2019–2025

Across 208 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$704
  • Otsuka America Pharmaceutical, Inc.$581
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$416
  • Alkermes, Inc.$241
  • Takeda Pharmaceuticals U.S.A., Inc.$234
  • Lundbeck LLC$231
  • plus $647 from 7 others

What the payments were for

  • Food & beverage$2,84993%
  • Education$2067%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,054 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$72,606
Medicare patients
215
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate66$190,176
RexultiBrexpiprazole109$173,230
Abilify MaintenaAripiprazole62$169,257
VraylarCariprazine Hcl78$119,127
Invega TrinzaPaliperidone Palmitate12$103,797
Risperdal ConstaRisperidone Microspheres25$46,208
AustedoDeutetrabenazine12$45,228
Risperidone ErRisperidone Microspheres14$42,613
TrintellixVortioxetine Hydrobromide72$33,890
Aripiprazole709$26,411
Lurasidone Hcl157$24,996
Paliperidone ErPaliperidone75$17,104
Lamotrigine ErLamotrigine76$16,747
Asenapine Maleate50$16,436
Chlorpromazine Hcl47$15,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$581$342,487171 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$217$340,182103 claims
AbbVieVraylar$704$119,12778 claims
Teva Pharmaceuticals USA, Inc.Austedo$181$45,22812 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$234$39,05484 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →